An observational study in Anxiety Depression, Post Traumatic Stress Disorder and Mental Fatigue, sponsored by Centro Hospitalar Universitario do Algarve. Status unknown at 6 sites in Portugal. Open to participants aged 18 Years to 95 Years. Per ClinicalTrials.gov, last updated 2023-03-14.
Sponsored by Centro Hospitalar Universitario do Algarve · Observational
An association of fatigue with post-viral neuropsychological disturbs has been reported. Among patients hospitalized with COVID-19 there is an increased incidence of anxiety and depression symptoms. In addition, a quarter of patients experience at least mild symptoms of acute post traumatic stress disorder. (Mazza, M. G. et al 2020). The prevalence of chronic fatigue syndrome had a correlation with post-traumatic stress disorder (PTSD) in a study conducted after the outbreak of the COVID-19 in Iran (Silmani et al, 2021), that showed 5.8% of subjects suffering from PTSD after 6 months of SARS-CoV-2 infection onset.
In this Study we propose to use a tool to quantify the degree of physical and psychological fatigue in post-COVID-19 patients, and assess the correlation of fatigue with the neuropsychiatric sequelae in hospitalized and non hospitalized patients.
This study will address the neuropsychiatric sequelae that remain for at least 6 months after SARS-CoV-2 acute infection, as depression, anxiety and/or post-traumatic stress disorder.
The patiensts will be assessed at the post-COVID-19 outpatient clinics of five Portuguese Hospitals. In the first visit (T1) will be collected the demographic characteristics; the medical history; and the screening of acute disease symptoms and severity. In the second visit (T2), the time frame will be at least 6 months after the positive test and no longer than 9 months, a set of structured questionnaires will be provided, including: the Chalder Fatigue Scale, Anxiety and Depression Hospital Scale (HADS), The Posttraumatic Stress Symptoms-14 (PTSS-14) adapted to COVID-19 and the EuroQol 5-Dimensions (EQ-5D).
7,640 studies on the registry are indexed under COVID-19; 488 are open to participants now.
This study's planned enrollment of 200 is below the median of 261 across 3,136 observational studies indexed under COVID-19.
Browse COVID-19 studies →Centro Hospitalar Universitario do Algarve is the lead sponsor of 4 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
The study will be conducted in five Portuguese Hospitals, Universitary and district, in which a follow-up post-COVID-19 medical consultation has been implemented
Exclusion Criteria:
Post-COVID-19 symptomatic patients with neuropsychological sequelae
Other: Neuropsychological Sequelae
Post-COVID-19 symptomatic patients Without neuropsychological sequelae
Neuropsychological Sequelae after SARS-CoV-2 symtomatic infection
Prevalence of fatigue in patients with post-COVID-19 depression and/or anxiety
Fatigue will be assessed with the Chalder fatigue scale: - Global score (0-33), that also spans two dimensions-physical fatigue (measured by items 1-7) and psychological fatigue (measured by items 8-11). This is a Likert scoring system that allows for means and distributions to be calculated for both the global total as well as the two sub-scales. Depression and anxiety will be assessed with the Hospital Anxiety and Depression Scale * Depression HADS subscale scoring: Normal 0-7; Boderline abnormal 8-10; Abnormal 11-21 * Anxiety HADS subscale scoring: Normal 0-7; Borderline 8-10; Abnormal 11-21
Time frame: 6-9 months
Prevalence of fatigue in patients with post-COVID-19 post-traumatic stress disorder
Fatigue will be assessed with the Chalder fatigue scale (global and binary score). PTSD will be assessed with the Post-Traumatic Stress Syndrome 14 Questions Inventory (PTSS-14) adapted to COVID-19: - Positive case between 46-98 points
Time frame: 6-9 months
Impact of post-COVID-19 fatigue in quality of life.
Fatigue will be assessed with the Chalder fatigue scale (binary score and global score). Quality of live will be assessed by the original EQ-5D questionnaire, that comprises two parts: - EQ-5D-3L, health state classification scheme of five items (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), each having three alternatives (1= no problems, 2= moderate problems, and 3= severe problems). Calculating a single index score combines these five dimensions. The index value of a particular health state thus indicates the preference for being in that health state in relation to death, which has been set equal to 0 and best possible health (eg, no problems on any of the five items) which has been set to 1.0. - EQ VAS, a visual analog scale to health state ranging from 0 (worst possible health state) to 100 (best possible health state).
Time frame: 6-9 months
Impact of post-COVID-19 neuropsychological sequelae in quality of life
Evaluate if the positive cases for anxiety, depression and/or PTSD have lower quality of live (The tools will be the same of previous outcomes).
Time frame: 6-9 months
Evaluate if neuropsychological are associated with severity of acute COVID-19
Depression and anxiety will be assessed with the Hospital Anxiety and Depression Scale * Depression HADS subscale scoring: Normal 0-7; Boderline abnormal 8-10; Abnormal 11-21 * Anxiety HADS subscale scoring: Normal 0-7; Borderline 8-10; Abnormal 11-21 Posttraumatic Stress Symptoms-14 instrument, adapted in this protocol for COVID-19 survivors: - PTSS 14 scoring \> 45 points Acute COVID-19 severity will be categorized as mild illness (mild symptoms without the radiographic appearance of pneumonia), pneumonia (having symptoms and the radiographic evidence of pneumonia, with no requirement for supplemental oxygen), severe pneumonia (having pneumonia, including one of the following: respiratory rate \> 30 breaths/minute; severe respiratory distress; or SpO2 ≤ 93% on room air at rest), and critical cases (e.g. respiratory failure requiring mechanical ventilation or nasal high flow oxygen, septic shock, other organ failure occurrence or admission into the ICU).
Time frame: 6-9 months
Plan to share: Undecided
This study is status unknown, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centro Hospitalar Universitario do Algarve